RECRUITING

Intralesional Cyclosporine for Alopecia Areata

Talk to us

Conditions

Alopecia AreataCyclosporineIntralesional Injection

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Alopecia areata (AA) is a chronic autoimmune disease that causes non-scarring, focal areas of hair loss. Due to its resulting disfigurement and unpredictable course, it is recognized as a serious medical condition with severe emotional and psychosocial distress, including a high prevalence of depression and anxiety.1-4 Treatment options for alopecia areata are limited. Cyclosporine has been used as an effective therapeutic option in the treatment of psoriasis. Additionally, the use of oral cyclosporine, alone or in combination with other agents, has been used in the management of a multitude of dermatologic conditions, including alopecia areata, pyoderma gangrenosum, chronic idiopathic purpura, atopic dermatitis, dyshidrotic eczema, Behcet disease, dermatomyositis, among others.8 Although cyclosporine has demonstrated efficacy in the management of these diseases, systemic side effects of oral cyclosporine often limit its long-term use. However, intralesional injections of cyclosporine have not been investigated. Through this randomized double-blind placebo-controlled clinical study, the study team aims to evaluate the safety, dosing, and efficacy of intralesional cyclosporine for use in the treatment of alopecia areata. The study team expects about 12 people at UC Davis to take part in this research. The study itself includes 11 visits and will last about 12 weeks.

Official Title

Pilot Study on Intralesional Cyclosporine for Alopecia Areata

Quick Facts

Study Start:2025-07-01
Study Completion:2026-10-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07029204

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age between 18 and 65 at screening visit.
  2. * Diagnosis of alopecia areata by a board-certified dermatologist at screening visit.
  3. * Current alopecia areata episode involving the scalp of more than 3 months' duration prior to baseline visit.
  4. * SALT Score between 10 and 50 at baseline visit.
  5. * Stable disease based on subject history over the past 1 month.
  6. * Agree not to use any alopecia areata treatments during the study, including, but not limited to: systemic therapies (eg, methotrexate, cyclosporine, corticosteroids, JAK inhibitors) and biologics (eg, monoclonal antibodies), intralesional corticosteroid injections, topical therapies, and phototherapy
  1. * Currently experiencing other forms of alopecia. Including but not limited to: androgenetic alopecia, telogen effluvium, or any other concomitant conditions (eg, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis) that could interfere with evaluation of alopecia areata
  2. * Previous treatment with cyclosporine
  3. * Other autoimmune diseases
  4. * Pregnancy or lactation
  5. * Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking study drug or interfere with the interpretation of data. These may include, but are not limited to, patients with untreated hypertension, patients with known renal disease with decreased GFR, and known infection.
  6. * Adults unable to consent
  7. * Prisoners
  8. * Currently using drugs that are well-substantiated to interact with cyclosporine, including the following: ciprofloxacin, gentamicin, tobramycin, trimethoprim with sulfamethaxazole, vancomycin, melphalan, amphotericin B, ketoconazole, azapropazon, colchicine, diclofenac, naproxen, sulindac, cimetidine, ranitidine, tacrolimus, fibric acid derivatives (e.g. bezafibrate, fenofibrate), and methotrexate.

Contacts and Locations

Study Contact

Salsala Nasim, BS
CONTACT
916-551-2636
sanasim@ucdavis.edu

Principal Investigator

Oma Agbai, MD
PRINCIPAL_INVESTIGATOR
UC Davis Health Department of Dermatology

Study Locations (Sites)

University of California, Davis - Dermatology Department
Sacramento, California, 95816
United States

Collaborators and Investigators

Sponsor: University of California, Davis

  • Oma Agbai, MD, PRINCIPAL_INVESTIGATOR, UC Davis Health Department of Dermatology

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-01
Study Completion Date2026-10-01

Study Record Updates

Study Start Date2025-07-01
Study Completion Date2026-10-01

Terms related to this study

Keywords Provided by Researchers

  • Alopecia Areata
  • Cyclosporine
  • Intralesional Injection

Additional Relevant MeSH Terms

  • Alopecia Areata